Protara Therapeutics Reports Second-Quarter 2023 Net Loss of $11.3 Million

Protara Therapeutics, Inc.(TARA) and its subsidiaries released t heir unaudited condensed consolidated financial statements for the second quarter ended June 30, 2023. The company reported a net loss of $11.3 million for the quarter. Additionally, the revenue for the same period amounted to $846,000.

Condensed Consolidated Balance Sheets

The Condensed Consolidated Balance Sheets revealed that as of June 30, 2023, Protara Therapeutics had total assets valued at $95.1 million. This represented a decrease from the $113.3 million reported as of December 31, 2022. The company's assets were primarily comprised of cash and cash equivalents, amounting to $33.9 million, and marketable debt securities totaling $46.4 million.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss